Upgrade to SI Premium - Free Trial

RBC Capital Reiterates Outperform on Abbvie (ABBV) Ahead of Numerous Catalysts

May 3, 2021 7:14 AM
RBC Capital analyst Daniel Busb reiterated the $135.00 price target on Abbvie (NYSE: ABBV) while maintaining a Outperform rating after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View

Next Articles